Business
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company’s Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I be
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c_DX5f.kGlw2uEkCuplsLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/c_DX5f.kGlw2uEkCuplsLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Stephen Willard","length":15,"tagName":"p"},{"type":"image","alt":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","displaySize":"","headline":null,"caption":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":199,"height":279,"url":"https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/miDSk8a9XnBB50taEFoeVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTUwNQ--/https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff","width":199,"height":279},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/miDSk8a9XnBB50taEFoeVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTUwNQ--/https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff","width":199,"height":279}}},{"type":"text","content":"MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company’s Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders.","length":346,"tagName":"p"},{"type":"text","content":"Dear Fellow Stockholders,","length":25,"tagName":"p"},{"type":"text","content":"I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B®). Longeveron is progressing through a significant inflection point in the Company’s history.","lengt...